Highlights Neuren Pharmaceuticals Limited

Equities

NEU

NZNEUE0001S8

Market Closed - Australian S.E. Other stock markets 02:10:53 2024-05-16 EDT			5-day change	1st Jan Change
21.8 ^AUD	+2.16%		+12.89%	-12.70%

05-09	Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million	MT
04-24	Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million	05-09	MT
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	04-22	MT
Neuren Pharmaceuticals Limited Provides Sales Guidance for the First Quarter and Full Year 2024	02-29	CI
Neuren Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023	23-08-27	CI
Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Neuren Pharmaceuticals Jumps 17% After Global Expansion of DAYBUE Partnership	23-07-13	MT
Neuren Pharmaceuticals' License Partner Launches Neurological Drug in the US	23-04-18	MT
U.S. FDA approves Acadia's Rett syndrome drug (March 10)	23-03-10	RE
Neuren Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA	23-01-22	CI
Neuren Pharmaceuticals Advances Regulatory Approvals and Clinical Trials for Neurological Drug	22-12-26	MT
Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials	22-12-22	CI
Neuren Pharmaceuticals Receives $10 Million Milestone Payment	22-10-20	MT
US FDA Accepts Neuren Pharmaceuticals' Licensed Drug for Use in Rhett Syndrome; Shares Rise 4%	22-09-12	MT
Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration	22-09-12	CI
Neuren Pharmaceuticals Narrows H1 Net Loss by 11%	22-08-24	MT
Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-23	CI
Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS	22-08-07	CI
Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman	22-07-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neuren Pharmaceuticals Limited

Equities

NEU

NZNEUE0001S8

Highlights

Filters